{"id":"https://openalex.org/W2591081971","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.4610","title":"Analysis of the relationship between Karnofsky performance status (KPS) and tumor response in the RECORD-1 phase III trial of everolimus in patients with advanced renal cell carcinoma (RCC).","display_name":"Analysis of the relationship between Karnofsky performance status (KPS) and tumor response in the RECORD-1 phase III trial of everolimus in patients with advanced renal cell carcinoma (RCC).","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2591081971","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.4610","mag":"2591081971"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.4610","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.4610","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.4610","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018910230","display_name":"Camillo Porta","orcid":"https://orcid.org/0000-0003-2412-1563","observed_orcids":["https://orcid.org/0000-0003-2412-1563"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Porta","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049672639","display_name":"Bernard J. Escudier","orcid":"https://orcid.org/0000-0002-4626-0479","observed_orcids":["https://orcid.org/0000-0002-4626-0479"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. Escudier","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102785664","display_name":"Thomas E. Hutson","orcid":"https://orcid.org/0000-0002-4529-4212","observed_orcids":["https://orcid.org/0000-0002-4529-4212"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. E. Hutson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050649350","display_name":"Robert A. Figlin","orcid":"https://orcid.org/0000-0002-6323-6075","observed_orcids":["https://orcid.org/0000-0002-6323-6075"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. A. Figlin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053069942","display_name":"Emiliano Calvo","orcid":"https://orcid.org/0000-0003-4921-829X","observed_orcids":["https://orcid.org/0000-0003-4921-829X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Calvo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001987856","display_name":"Viktor Gr\u00fcnwald","orcid":"https://orcid.org/0000-0003-2083-7687","observed_orcids":["https://orcid.org/0000-0003-2083-7687"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. Gr\u00fcnwald","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112221965","display_name":"Suzanne Osanto","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Osanto","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040832651","display_name":"Alain Ravaud","orcid":"https://orcid.org/0000-0001-9455-6744","observed_orcids":["https://orcid.org/0000-0001-9455-6744"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Ravaud","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"A. Panneerselvam","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Panneerselvam","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110680473","display_name":"J. J. Knox","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. J. Knox","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5059063118","display_name":"Robert John Motzer","orcid":"https://orcid.org/0000-0001-6925-2327","observed_orcids":["https://orcid.org/0000-0001-6925-2327"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. J. Motzer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"4610","last_page":"4610"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11297","display_name":"Ferroptosis and cancer prognosis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/karnofsky-performance-status","display_name":"Karnofsky performance status","score":0.9089999794960022},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.8009999990463257},{"id":"https://openalex.org/keywords/metastatic-renal-cell-carcinoma","display_name":"metastatic renal cell carcinoma","score":0.8769999742507935},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.6570000052452087},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7760000228881836},{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.5820000171661377},{"id":"https://openalex.org/keywords/sunitinib","display_name":"sunitinib","score":0.6629999876022339},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.949999988079071},{"id":"https://openalex.org/keywords/recist-response-assessment","display_name":"RECIST response assessment","score":0.6349999904632568},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.5690000057220459},{"id":"https://openalex.org/keywords/best-supportive-care","display_name":"best supportive care","score":0.5730000138282776}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9387623071670532},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.9381738901138306},{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.7978201508522034},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.7524233460426331},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6905955672264099},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6674269437789917},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.5772768259048462},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.47671952843666077},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.4534466862678528},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.45309972763061523},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.435647577047348},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40471285581588745},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.39689356088638306},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.38487309217453003},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.24718284606933594},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.13082915544509888},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.4610","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.4610","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.4610","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.7599999904632568,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3033250867","https://openalex.org/W2467423746","https://openalex.org/W1979752037","https://openalex.org/W2165631523","https://openalex.org/W2138129102","https://openalex.org/W2026023947","https://openalex.org/W2298717328","https://openalex.org/W2102478789","https://openalex.org/W2590079114","https://openalex.org/W2589896733"],"abstract_inverted_index":{"4610":[0],"Background:":[1],"In":[2,212,255,290],"the":[3,35,52,216,256,266,296,323],"RECORD-1":[4,49],"phase":[5],"III":[6],"trial":[7],"of":[8,25,48,124,130,187,258,268,298,322,327],"patients":[9,26,77,139,146,154,190,240,259,305,330],"with":[10,191,223,241,260,306,312,331],"metastatic":[11],"RCC":[12],"who":[13,168,333],"failed":[14],"initial":[15,88,335],"sunitinib":[16,89,336],"or":[17,90,100,177,243,337],"sorafenib,":[18],"everolimus":[19,32,94,273,292,309,328],"reduced":[20,295],"tumor":[21,66,228,247],"burden":[22,248],"in":[23,65,150,165,218,227,246,263,304,329],"47%":[24],"(vs":[27],"10%":[28],"on":[29,87],"placebo).":[30],"Notably,":[31],"also":[33],"prolonged":[34,275],"time":[36],"to":[37,115],"KPS":[38,55,80,117,136,151,188,219,251,264,299],"deterioration":[39,56,149,186,262,300],"(\u226510%)":[40],"(5.78":[41],"vs":[42,159,210,277,280],"3.84":[43],"months).":[44],"This":[45],"retrospective":[46],"analysis":[47],"further":[50,320],"explores":[51],"relationship":[53],"between":[54],"and":[57,71,82,128,294,325],"response":[58,110,172],"(as":[59],"measured":[60],"by":[61],"best":[62,68,106,224],"percent":[63,225],"change":[64,217,226],"size,":[67],"overall":[69],"response,":[70],"progression-free":[72],"survival":[73],"[PFS]).":[74],"Methods:":[75],"Eligible":[76],"had":[78,184],"baseline":[79,135],"\u226570%":[81],"measurable":[83],"mRCC":[84,332],"that":[85,238],"progressed":[86],"sorafenib.":[91,338],"Patients":[92,164],"received":[93],"10":[95],"mg/day":[96],"(n":[97,102],"=":[98,103,157,162,175,182,196,200,206,235,284],"277)":[99],"placebo":[101,278],"139)":[104],"plus":[105],"supportive":[107],"care.":[108],"Tumor":[109],"was":[111,118,140,220,310],"assessed":[112],"centrally":[113],"according":[114],"RECIST.":[116],"determined":[119],"at":[120,265],"baseline,":[121],"day":[122],"1":[123],"each":[125],"28-day":[126],"cycle,":[127],"end":[129,267],"study":[131,143,269],"treatment.":[132],"Results:":[133],"Mean":[134],"for":[137,208],"all":[138],"88%.":[141],"At":[142],"end,":[144],"everolimus-treated":[145,213],"showed":[147],"less":[148,185],"than":[152,189],"placebo-treated":[153],"(mean":[155],"\u0394KPS":[156,199],"\u22128.08":[158],"\u221213.09;":[160],"P":[161,205,234,286],"0.025).":[163],"either":[166],"arm":[167],"achieved":[169],"a":[170],"partial":[171],"(PR,":[173],"n":[174,181,195],"5)":[176],"stable":[178,307],"disease":[179,193],"(SD,":[180],"229)":[183],"progressive":[192],"(PD,":[194],"131):":[197],"mean":[198],"\u22122.00,":[201],"\u22127.03,":[202],"\u221214.50,":[203],"respectively;":[204],"0.002":[207],"SD":[209],"PD.":[211],"patients,":[214],"however,":[215],"not":[221],"correlated":[222],"size":[229],"(Pearson":[230],"correlation":[231],"coefficient,":[232],"0.050;":[233],"0.489),":[236],"suggesting":[237],"even":[239],"minimal":[242],"no":[244,261],"reduction":[245],"may":[249],"derive":[250],"benefit":[252],"from":[253],"everolimus.":[254],"subgroup":[257],"treatment":[270],"(\u0394KPS":[271],"\u22650),":[272],"significantly":[274],"PFS":[276,314],"(4.90":[279],"3.48":[281],"months,":[282],"HR":[283],"0.44,":[285],"<":[287],"0.001).":[288],"Conclusions:":[289],"RECORD-1,":[291],"delayed":[293],"degree":[297],"versus":[301],"placebo.":[302,316],"Furthermore,":[303],"KPS,":[308],"associated":[311],"improved":[313],"over":[315],"These":[317],"results":[318],"provide":[319],"evidence":[321],"efficacy":[324],"tolerability":[326],"fail":[334]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2017-03-03T00:00:00"}